期刊
EMBO REPORTS
卷 14, 期 4, 页码 328-336出版社
WILEY
DOI: 10.1038/embor.2013.20
关键词
apoptosis; mitochondria; Bcl2; caspase; proteasome
资金
- Canadian Institutes of Health Research [FRN6192]
- Consortium quebecois sur la decouverte du medicament
- Genome Quebec
- German Research Foundation (Forschungsstipendium) [GZ: ER 678/1-1]
The Bcl2 pro-survival protein family has long been recognized for its important contributions to cancer. At elevated levels relative to pro-apoptotic effector members, the survival proteins prevent cancer cells from initiating apoptosis in the face of many intrinsic tumour-suppressing pathways and extrinsic therapeutic treatments aimed at controlling tumorigenesis. Recent studies, including genome-wide analyses, have begun to focus attention on a particularly enigmatic member of the family-myeloid cell leukaemia 1 (Mcl1). For reasons that are not clear, Mcl1 in cancer-cells is turned over rapidly, eliminated primarily through the ubiquitin-proteasome pathway. Moreover, the mechanistic aspects of this constitutive membrane-associated protein have not been fully elucidated. As the pro-cancer activity of Mcl1 requires elevated expression levels of the protein, the cancer genome adapts to ensure either high levels of synthesis or evasion of degradation, or both. Here, we focus on the complex strategies at play and their therapeutic implications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据